MRNA Add to watchlist
$67.01 +0.00 (+0.00%)
Pre-Market: $67.44 +0.43 (+0.64%)
Last updated: Jul 15, 2026 09:21
52-Week Range
$67.44
$22.28 $67.44 $85.60

Fundamentals Overview

Moderna, Inc. is in the middle of its 52-week range with premium valuation, trading relatively flat today.

Valuation premium

P/B 3.6 P/S 12.03

Risk (Beta)

0.94 — in line vol

BullzEye Analysis

Our composite tilts Hold on technicals (e.g. RSI, ADX, trend), fundamentals, sentiment, sector and index context, and risk.

Composite Signal

Sell
Buy
Hold — 58% confidence Risk: Moderate Volatility — Beta 0.94. Diversify and only invest what you can afford to lose.

Supporting (Buy):

3M vs S&P 500: +23.5% · 3M vs Healthcare sector: +26.1%

Not financial advice. For education and research only; do your own research and consider a financial advisor before investing.

Key Stats

Market Cap
$26.76B
P/E (TTM)
N/A
EPS (TTM)
N/A
Dividend Yield
N/A
52-Week Range
$22.28 - $85.60
Volume vs Avg
N/A
Beta
0.94

About

Moderna, Inc., a biotechnology firm, is dedicated to the discovery, development, and commercialization of messenger RNA (mRNA) based therapies and preventive medicines. Its extensive research and development efforts target a broad spectrum of medical needs, including infectious diseases, cancer immunology, rare conditions, cardiovascular ailments, and autoimmune disorders, with operations spanning the United States, Europe, and other global markets. The company's diverse product pipeline encompa...
Sector: Healthcare
Headquarters: US
Employees: 4,700
IPO Date: Dec 2018
Beta: 0.94 (Less volatile than market)

Ratings & Grades at a Glance

Overall rating: C. Current institutional positions: Buy: 2, Equal Weight: 6, Hold: 1, In Line: 2, Neutral: 4, Overweight: 3, Sector Perform: 4, Underperform: 6, Underweight: 2.

Financial story & AI narrative

Open this tab to load the financial story.

Valuation & Ratios

Valuation, liquidity, and profitability metrics are consolidated here (including ratios that previously appeared in the Financials story). Trailing (TTM) vs forward-looking (e.g. DCF) is noted on each line where it matters.

DCF vs price: DCF estimate is $-1.74; current price is $67.44. That’s a -102.6% gap. When the gap is large (e.g. >20%), that’s divergence; when they’re close, that’s convergence. Differences can reflect growth expectations, sector premiums, or conservative vs. optimistic assumptions. Use DCF as one input alongside technicals and sentiment.

Metric Value
Valuation
P/E (TTM) N/A
PEG (TTM) N/A
P/B (TTM) 3.6
P/S (TTM) 12.03
Liquidity & enterprise
Current Ratio (TTM) 2.41
Quick Ratio (TTM) 2.35
Cash Ratio (TTM) 0.8
Profitability
ROE (TTM) N/A
ROA (TTM) N/A
Revenue growth (YoY) N/A
Net margin (TTM) -1.44%
Gross margin (TTM) -13.89%
Operating margin (TTM) -1.53%
Debt to equity (TTM) N/A

Latest News

News loads when you open this tab.

Price Target, Ratings & Grades

Analyst price targets, consensus, rating snapshot, and institutional grades for MRNA.

Analyst Sentiment at a Glance

C
Buy 2Equal Weight 6Hold 1In Line 2Neutral 4Overweight 3Sector Perform 4Underperform 6Underweight 2
Price Target Consensus
Current $67.44
Median $45.00
Consensus $46.50
Low consensus $35.00
High consensus $77.00

Stock Grades (Institutions)

Institution Action Previous Grade New Grade Date
Morgan Stanley maintain Equal Weight Equal Weight 2026-07-08
RBC Capital maintain Sector Perform Sector Perform 2026-07-07
B of A Securities maintain Underperform Underperform 2026-07-07
Piper Sandler maintain Overweight Overweight 2026-06-26
B of A Securities maintain Underperform Underperform 2026-06-08
RBC Capital maintain Sector Perform Sector Perform 2026-05-04
UBS maintain Neutral Neutral 2026-05-04
Evercore ISI Group maintain In Line In Line 2026-05-04
Goldman Sachs maintain Neutral Neutral 2026-05-04
Barclays maintain Equal Weight Equal Weight 2026-04-02
Piper Sandler maintain Overweight Overweight 2026-02-23
Evercore ISI Group maintain In Line In Line 2026-02-17
Goldman Sachs maintain Neutral Neutral 2026-02-17
RBC Capital maintain Sector Perform Sector Perform 2026-02-17
Morgan Stanley maintain Equal Weight Equal Weight 2025-12-12
Piper Sandler maintain Overweight Overweight 2025-11-21
Leerink Partners maintain Underperform Underperform 2025-11-21
RBC Capital maintain Sector Perform Sector Perform 2025-11-21
B of A Securities maintain Underperform Underperform 2025-11-10
Barclays maintain Equal Weight Equal Weight 2025-11-07
Citigroup maintain Neutral Neutral 2025-10-23
UBS maintain Buy Buy 2025-10-23
JP Morgan maintain Underweight Underweight 2025-10-23
Needham maintain Hold Hold 2025-10-20
Morgan Stanley maintain Equal Weight Equal Weight 2025-10-10
Leerink Partners maintain Underperform Underperform 2025-08-22
Barclays maintain Equal Weight Equal Weight 2025-08-04
B of A Securities maintain Underperform Underperform 2025-07-22
JP Morgan maintain Underweight Underweight 2025-05-22
UBS maintain Buy Buy 2025-05-02